Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
1996 | 1 |
2014 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Your search was processed without automatic term mapping because it retrieved zero results.
Page 1
Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial.
Leukemia. 2022 Jul;36(7):1870-1878. doi: 10.1038/s41375-022-01582-5. Epub 2022 May 13.
Leukemia. 2022.
PMID: 35562406
Clinical Trial.
Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexate-cytarabine-thiotepa-rituximab (MATRix; arm C). A second randomization allocated patients with responsive/stable disease to whole-b …
Enrolled patients were randomly assigned to receive methotrexate-cytarabine (arm A), or methotrexate-cytarabine-rituximab (B), or methotrexa …
Hematopoietic growth factors and treatment of testicular cancer: biological interactions, routine use and dose-intensive chemotherapy.
Bokemeyer C, Kuczyk MA, Köhne H, Einsele H, Kynast B, Schmoll HJ.
Bokemeyer C, et al.
Ann Hematol. 1996 Jan;72(1):1-9. doi: 10.1007/BF00663009.
Ann Hematol. 1996.
PMID: 8605273
Review.
Hematopoietic growth factors (HGFs), particularly G- and GM-CSF, have been investigated for the treatment of testicular cancer in order to (a) ameliorate chemotherapy-induced myelosuppression, (b) increase the dose intensity of treatment, or (c) generate peripheral blood s …
Hematopoietic growth factors (HGFs), particularly G- and GM-CSF, have been investigated for the treatment of testicular cancer in order to ( …
Item in Clipboard
Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K.
Wass M, et al.
Eur J Haematol. 2014 Mar;92(3):268-70. doi: 10.1111/ejh.12240. Epub 2014 Jan 10.
Eur J Haematol. 2014.
PMID: 24330038
No abstract available.
Item in Clipboard
Cite
Cite